anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cosmetic use of at least one polypeptide amino acid sequence encoded by a nucleic acid sequence represented in whole or part by a sequence of SEQ ID No. 1, SEQ ID No. 2 or their analogues or a fragment, or at least one nucleic acid sequence encoding the polypeptide, or at least one modulator of activity, stability or expression of the polypeptide as a agent or for the preparation of composition for preventing and/or treating the signs of dry skin, is claimed, where SEQ ID No. 1 or SEQ ID No. 2 is not defined. An independent claim is included for a process for characterizing a state of dryness of epithelium comprising: (a) determining the epithelium in a sample, containing a polypeptide or nucleic acid sequence encoding the polypeptide; and (b) comparing the concentration determined in step (a) to a reference value. ACTIVITY : Dermatological. MECHANISM OF ACTION : None given.
Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 2.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use capable of improving the elasticity, etc., of skin, eliminating the skin roughening, etc., and imparting a transparent feeling to the skin by including an extract of CAMU CAMU (botanical name: Myrciaria dubia), an ascorbic acid (derivative) and/or a placental extract and a polyhyric alcohol. SOLUTION: This skin preparation for external use is obtained by including (A) an extract of CAMU CAMU in an amount of 0.0001-5 wt.% expressed in terms of a dry solid, (B) (i) ascorbic acid (derivative) (e.g. L-ascorbic acid phosphate magnesium) and/or (ii) a placental extract and (C) 0.001-80 wt.% of a polyhydric alcohol (e.g. trehalose). The content of the ingredient B is preferably 0.0001-10 wt.% in the case of the ingredient (i) and 0.0001-5 wt.% expressed in terms of a dry solid in the case of the ingredient (ii). The ingredient A is prepared by extraction thereof from a fruit of CAMU CAMU which is a fruit tree of the family Myrtaceae under conditions of a low temperature or heating.
Erectile dysfunction (ED) is an inability to provide adequate erection to initiate or maintain any sexual activity. The ED prevalence in adult males is approximately 20%. Cardiovascular diseases, diabetes mellitus(DM), chronic systemic diseases, smoking and obesity are among the aetiology of ED .In recent years, publications indicating that active inflammatory processes cause ED are increasing. In these studies where neutrophil- lymphocyte (NLR) and platelet-lymphocyte ratios (PLR) were used as signs of inflammation, a significant relationship was found between diseases with these proportions .Neutrophil-to-lymphocyte ratio (NLR) is a simple parameter to assess easily the inflammatory status of a subject. It has proven its usefulness in the stratification of mortality in major cardiac events , as a strong prognostic factor in several types of cancers , or as a predictor and a marker of inflammatory or infectious pathologies (such is pediatric appendicitis) and postoperative complications. Through enhanced production of cytokines and expression of cellular adhesion molecules, the dysfunctional endothelium promotes inflammation within the vascular wall and sets the stage for initiation and progression of atherosclerotic lesions in both penile vasculature and in peripheral and coronary blood vessels. It has been shown that patients with vasculogenic ED have increased inflammatory activation compared to subjects without ED.There are numerous studies suggesting that phosphodiesterase-5(PDE-5) inhibitors, which are the first-line therapy of ED, might be effective in reversing generalized endothelial dysfunction. Chronic treatment restores endothelium-dependent relaxations at various sites of the vascular tree, even up to one week after cessation of the treatment . Previous studies reported a chronic effect of sildenafil and tadalafil on endothelial function and pro-inflammatory markers/mediators including intercellular and vascular cell adhesion molecules-1 (ICAM-1 and VCAM-1, respectively), high sensitivity C-reactive protein (hsCRP), and interleukin-6
PROBLEM TO BE SOLVED: To obtain the subject composition which is a nonelution type dental polymer, useful for a dental resin material and capable of manifesting antimicrobial activities only on the surface by including a specific vinylbenzylphosphonium salt-based monomer as an active ingredient therein. SOLUTION: This antimicrobial and dental composition comprises a vinylbenzylammonium salt-based monomer represented by formula I [R<1> to R<3> are each H, a 1-18C alkyl, etc.; X<-> is an anion; (n) is a number or >=1] [e.g. 4-(tri-n-butylphosphoniomethyl)styrene chloride] as an active ingredient. The monomer represented by formula I is obtained by reacting a styrene derivative represented by formula II with a triorganophosphine in the presence of an organic solvent and a polymerization inhibitor at 25-110 deg.C reactional temperature. The amount of the compounded monomer is preferably 0.1-4mol% in the objective composition.
PURPOSE: To provide an antisweating agent or preventive compsn. against diaper dermatitis which contains natural or synthetic substance as an effective component and has good appearance and texture compared to a conventional ointment compsn. CONSTITUTION: This antiurease cosmetic product or dermatologic comspn. contains an effective amt. of condensed tannin and chlorogenic acid deriv. of locust bean or hamamelis in combination with a proper cosmetic base. More particularly, the compsn. is an antisweating agent and a preventive comspn. against diaper dermatitis.
This study will examine clinical and immunologic data and HIV-1 RNA levels in banked serum specimens from HIV-infected pediatric patients previously enrolled on NCI protocol 88-C-0219, a phase I/II study of 2', 3'-dideoxyinosine (ddI). In the original study serum p24 antigen was used as the direct measurement of viral quantitation. Advances in understanding of HIV pathophysiology have demonstrated that HIV-1 RNA level as measured by quantitative RNA PCR is a far superior molecular tool for assessing viral replication and burden in vivo. Analysis of clinical, HIV-1 RNA and CD4 responses will be performed to identify patients with discordant surrogate marker responses to therapy, defined as: improvement in immunologic parameters in the setting of virologic non-response or failure. Correlation will then be made with short and long term clinical outcomes.

Following the initial analysis to identify patients with discordant responses, selenium levels, viral genotypic and phenotypic profiles of resistance to ddI, and in vitro viral fitness will be examined. These biologic parameters have recently been determined to potentially play an important role in clinical, immunologic and virologic HIV-related outcomes. Parameters will be examined in subsets of patients with the following surrogate marker response profiles: a.) immunologic and virologic responders; b.) immunologic and virologic non-responders; and c.) discordant immunologic and virologic responders. Specimens from the ddI monotherapy study were chosen for this analysis because a substantial body of clinical and immunologic data is available on patients up to 7 years.
The primary aim of this study is to compare the instantaneous and total consumption of sevoflurane using 2 different concentrations and different minute / fresh gas flow to fill the system in the initial phase of anesthesia. Its secondary purpose is to compare the depth of anesthesia and hemodynamic parameters between the two groups.

A total of 70 patients between the ages of 18-65 will be included in the study.in 2.5 % sevoflurane grup After reaching 1 MAC level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration in the initial stage in 35 patients, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC. in sevoflurane 8 % group for 35 patients, after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC. . The depth of anesthesia for both groups will be measured by the Bispectral Index (BIS). BIS values between 40 and 60 are appropriate values for general anesthesia, for this value 1 MAC sevoflurane inhalation anesthesia and remifentanil infusion (0.1-0.3mcg / kg / min) will be used.
Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
Group 1A is where more than 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
Epilepsy is a chronic and heterogenous disease characterized by recurrent unprovoked seizures, that are commonly resistant to antiseizure medications. This study applies a transcriptome network-based approach across epilepsies aiming to improve understanding of molecular disease pathobiology, recognize affected biological mechanisms and apply causal reasoning to identify therapeutic hypotheses. This study included the most common drug-resistant epilepsies (DREs), such as temporal lobe epilepsy with hippocampal sclerosis (TLE-HS), and mTOR pathway-related malformations of cortical development (mTORopathies). This systematic comparison characterized the global molecular signature of epilepsies, elucidating the key underlying mechanisms of disease pathology including neurotransmission and synaptic plasticity, brain extracellular matrix and energy metabolism. In addition, specific dysregulations in neuroinflammation and oligodendrocyte function were observed in TLE-HS and mTORopathies, respectively. The aforementioned mechanisms are proposed as molecular hallmarks of DRE with the identified upstream regulators offering opportunities for drug-target discovery and development.
Disclosed is a system and a method for determining an injectable amount of bile required for a patient after gallbladder removal. The system comprises a receiving module, a creating module, and a determining module. The receiving module may receive a bile-flow rate, physiological parameters of a patient, and amount of fatty food in an alimentary tract of the patient. Based on these data received, the creating module may create a graph. Further, the determining module may determine a correlation between the bile-flow rate and the amount of fatty food in the alimentary tract based on the graph created. The correlation may be determined corresponding to a normal person and the patient which may be seen by two separate curves on the graph. Further, the determining module may determine an injectable amount of bile required for the patient based on the correlation.
These youth will receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 \[Cohort 1\] or 2018-19 and 2019-20 \[Cohort 2\]. These young women will participate in weekly group therapy and skill-building sessions, led by master's level clinicians, and will also receive individual support and therapy from their clinicians as-needed.
Forkhead box O3a (FOXO3a)-mediated mitochondrial dysfunction plays a pivotal effect on cardiac hypertrophy and heart failure (HF). However, the role and underlying mechanisms of FOXO3a, regulated by breviscapine (BRE), on mitochondrial function in HF therapy remain unclear. This study reveals that BRE-induced nuclear translocation of FOXO3a facilitates mitofusin-1 (MFN-1)-dependent mitochondrial fusion in cardiac hypertrophy and HF. BRE effectively promotes cardiac function and ameliorates cardiac remodeling in pressure overload-induced mice. In addition, BRE mitigates phenylephrine (PE)-induced cardiac hypertrophy in cardiomyocytes and fibrosis remodeling in fibroblasts by inhibiting ROS production and promoting mitochondrial fusion, respectively. Transcriptomics analysis underscores the close association between the FOXO pathway and the protective effect of BRE against HF, with FOXO3a emerging as a potential target of BRE. BRE potentiates the nuclear translocation of FOXO3a by attenuating its phosphorylation, other than its acetylation in cardiac hypertrophy. Mechanistically, over-expression of FOXO3a significantly inhibits cardiac hypertrophy and mitochondrial injury by promoting MFN-1-mediated mitochondrial fusion. Furthermore, BRE demonstrates its ability to substantially curb cardiac hypertrophy, reduce mitochondrial ROS production, and enhance MFN-1-mediated mitochondrial fusion through a FOXO3a-dependent mechanism. In conclusion, nuclear FOXO3a translocation induced by BRE presents a successful therapeutic avenue for addressing cardiac hypertrophy and HF through promoting MFN-1-dependent mitochondrial fusion.
PURPOSE: Adequate post-cesarean delivery analgesia can be difficult to achieve for women diagnosed with opioid use disorder receiving buprenorphine. We sought to determine if neuraxial clonidine administration is associated with decreased opioid consumption and pain scores following cesarean delivery in women receiving chronic buprenorphine therapy.
METHODS: This was a retrospective cohort study at a tertiary care teaching hospital of women undergoing cesarean delivery with or without neuraxial clonidine administration while receiving chronic buprenorphine. The primary outcome was opioid consumption (in morphine milligram equivalents) 0-6 h following cesarean delivery. Secondary outcomes included opioid consumption 0-24 h post-cesarean, median postoperative pain scores 0-24 h, and rates of intraoperative anesthetic supplementation. Multivariable analysis evaluating the adjusted effects of neuraxial clonidine on outcomes was conducted using linear regression, proportional odds model, and logistic regression separately.
RESULTS: 196 women met inclusion criteria, of which 145 (74%) received neuraxial clonidine while 51 (26%) did not. In univariate analysis, there was no significant difference in opioid consumption 0-6 h post-cesarean delivery between the clonidine (8 [IQR 0, 15]) and control (1 [IQR 0, 8]) groups (P = 0.14). After adjusting for potential confounders, there remained no significant association with neuraxial clonidine administration 0-6 h (Difference in means 2.77, 95% CI [- 0.89 to 6.44], P = 0.14) or 0-24 h (Difference in means 8.56, 95% CI [- 16.99 to 34.11], P = 0.51).
CONCLUSION: In parturients receiving chronic buprenorphine therapy at the time of cesarean delivery, neuraxial clonidine administration was not associated with decreased postoperative opioid consumption, median pain scores, or the need for intraoperative supplementation.
This study will evaluate up to 15 subjects in each age group for a period of 8-10 weeks performing neurocognitive tests before and after each intervention. The first study phase will be up to 2 weeks of a training period to allow participants to get acquainted with the use of the CGM if they are not familiar with the use of the device. This training period will be followed by a 4-week sensor-augmented pump (SAP) period using a study CGM and the subject's personal insulin pump. The subjects will return to clinic at the completion of the SAP period and will be trained on the Tandem t:slim X2 with Control-IQ and G6 CGM. At the completion of the system training session, subjects will begin 4-weeks of Closed-Loop Control (CLC). Questionnaires will be completed by the study subject at screening, after completion of SAP and after completion of CLC. Ecological Momentary Assessments (EMAs) and actigraphy data will be collected in the last 14 days of the SAP and CLC periods.

A parent/guardian of the enrolled children will also be asked to participate in all trainings, complete parental Patient-Report Outcomes (PRO) Questionnaires, and collect sleep patterns while wearing the actigraph watch.
PURPOSE:To provide a fluidity improver which allows the fluidity of powder to be greatly improved and retained over a long period of time, consisting of fine silica powder made hydrophobic with a specified diorganosiloxane oligomer. CONSTITUTION:1-50pts.wt. diorganosiloxane oligomer of the formula (wherein R is a monovalent hydrocarbon group; n is 1-15; Q is halogen, hydroxyl or OR<1>; and R<1> is a monovalent hydrocarbon group) is added to 100pts.wt. fine silica powder having a very low water content (e.g., fumed silica). The mixture is mixed until a homogeneous mixture is formed. The mixture is heated at 100-200 deg.C to make the powder hydrophobic, thus obtaining a fluidity improver having such characteristics that its specific surface area (BET method) is 180+ or -100m<2>; its carbon content is 5+ or -3wt%; its apparent density is 75+ or -35g/l; its compression density is 220+ or -35mg/cm<2> when 1.5g of a sample is placed under a pressure of 3.4kg/cm<2> for 4min; and its silanol titer is 1.0+ or -1.0ml; the titer being expressed by the titer of an aq. soln. of 0.1N-NaOH required for changing the pH of a dispersion from 4.0-9.0. The dispersion obtd. by dispersing 2.0g of a sample in a liquid mixture of 25ml of ethanol and 75ml of a 20wt% aq. soln. of NaCl. 0.2-0.3wt% said fluidity improver is added to powder.
Serotonin regulates multiple physiological and pathological processes in the brain, including mood and cognition. The serotonin receptors 5-HT1AR (also known as HTR1A) and 5-HT7R (also known as HTR7) have emerged as key players in stress-related disorders, particularly depression. These receptors can form heterodimers, which influence their functions. Here, we explored the developmental dynamics of 5-HT1AR and 5-HT7R expression and validated heterodimerization levels in the brain of control and stressed mice. In control animals, we found that there was an increase in 5-HT1AR expression over 5-HT7R in the prefrontal cortex (PFC) and hippocampus during development. Using a chronic unpredictable stress as a depression model, we found an increase in 5-HT7R expression exclusively in the PFC of resilient animals, whereas no changes in 5-HT1AR expression between control and anhedonic mice were obtained. Quantitative in situ analysis of heterodimerization revealed the PFC as the region exhibiting the highest abundance of 5-HT1AR-5-HT7R heterodimers. More importantly, upon chronic stress, the amount of heterodimers was significantly reduced only in PFC of anhedonic mice, whereas it was not affected in resilient animals. These results suggest an important role of brain-region-specific 5-HT1AR-5-HT7R heterodimerization for establishing depressive-like behaviour and for development of resiliency.
PURPOSE:To produce an antibody exhibiting extremely high specificity to a measuring object peptide antigen by the absorption operation of the specific antibody by the specific part peptide chain of a measuring target hormone. CONSTITUTION:First, a peptide type antigen is inoculated in an animal, by which the antibody for the peptide type antigen is formed in the body fluid of said animal. Said body may be any animal other than man. The body fluid contg. the formed antibody is drawn and this is put in contact with the peptide essential for formation of the specific antibody of the peptide type antigen which is insolubilized on a carrier. To this end, said body fluid is subjected to, for example, salting out and settling, and directly or after immune globulin G(IgG) fraction is fractionated by a column chromatography, it is put in contact with the insolubilized peptide. Thence, the specifically absorbed antibody is eluted by using, for example, a buffer of low pH or high pH and a buffer contg. salt of high concn.
The composition consists of red upborne elixir, calomel, sodium hydroxide, potassium nitrate, sulphur, when it is necessary to strengthen the efficacy of the drug, the arsenic is added to replace calomel. Said invention is a multifunctional drug. The therapeutic principle lies in that it not only can eliminate toxicity and kill fungi, but also can form the local thin air subcutaneous small area to make the bactera be suffocated and die. When it is used to treat dermatomycosis, the pain is small, the time is short and the result is thoroughness. It possesses of a definite curative effect for other dermatosis, such as acne, pudenda itching for both male and female, pruritus analis, wart, pruritus of skin, impetigo, psoriasis and tinea versicolor. The source of medicinal material is extensive and the cost is low.
This study will investigate the efficacy of phototherapy on improving sleep, in the form of a wearable neck device used at night. Phototherapy has been shown to improve chronic pain, cerebral blood flow, neurological function, and capillary growth in skeletal muscle. A device worn at night may improve sleep onset, total sleep time, or modify sleep architecture. Improved cardiovascular function may facilitate a decrease in core body temperature needed for sleep onset. Relaxation from direct heat may help to decrease cortisol levels, thus reducing the number of night-time arousals. It may also decrease circulating levels of norepinephrine (NE), one of the main neurotransmitters involved in arousal. The aim of this study is to evaluate if the device worn leads to greater next-day wellbeing and cognitive function as a result of increased slow-wave activity.
Patients should be advised that any change of cyclosporine formulation should be made cautiously and only under physician supervision because it may result in the need for a change in dosage.

Patients should be informed of the necessity of repeated laboratory tests while they are receiving the drug. They should be given careful dosage instructions, advised of the potential risks during pregnancy, and informed of the increased risk of neoplasia.

Patients using cyclosporine oral solution with its accompanying syringe for dosage measurement should be cautioned not to rinse the syringe either before or after use. Introduction of water into the product by any means will cause variation in dose.

Cyclosporine may impact the ability to drive and use machines. Patients should be advised to exercise care when driving or using machines if they experience neurological disturbances including confusion, somnolence, or dizziness and discuss with their healthcare provider (see WARNINGS and ADVERSE REACTIONS).
After each face to face session the patient will receive the exercises ordered by the physical therapist to perform at home. The exercises will be sent as a video to his/her mobile or e-mail according to the subject's preference. The exercises will be previously recorded and accompanied with a verbal explanation and instructions on how to correctly perform the exercises, paying close attention to specific points. In total, there will be 10 videos of exercises found effective for LBP patients.. After each face to face meeting, the physical therapist will choose from these 10 videos suitable exercises for the patients.
RSV is an important cause of serious respiratory infections in adults aged 60 years and older. The current study is divided into four cohorts, evaluating various doses and combinations of RSV preF-based vaccines. Cohort 1 will assess the safety and reactogenicity of different RSV preF-based vaccines. Cohort 2 is an expansion of cohort 1 and will assess both safety and immunogenicity of these different RSV vaccines. based on C1 and 2 data the optimal vaccine composition will be selected and further evaluated in Cohort 3 and 4 including durability and revaccination. Cohort 3 will accumulate safety data on the selected vaccine and optimize its formulation. Cohort 4 is an expansion of several arms in cohort 3, aimed to understand the durability of the immune response induced by the selected vaccine, and to explore the possibility for revaccination.